Pfizer Inc. Prepares to Release Q1 Earnings Amid Market Challenges

Pfizer Inc. (PFE), based in New York, is a leader in the biopharmaceutical industry, involved in the discovery, development, manufacturing, marketing, distribution, and sale of various products. The company boasts a market capitalization of $125.5 billion, offering a range of medicines, vaccines, medical devices, and consumer healthcare products across oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer is set to announce its fiscal first-quarter earnings for 2025 on Tuesday, April 29, before the market opens.

Analysts’ Expectations for Q1 Earnings

As the earnings announcement approaches, analysts predict that PFE will report earnings of $0.67 per share on a diluted basis. This figure represents an 18.3% decrease from the prior year’s $0.82 per share. Notably, Pfizer has consistently exceeded Wall Street’s EPS estimates in its last four quarterly reports.

Full-Year Projections

For the entire fiscal year, analysts expect Pfizer to report an EPS of $2.98, which is a decline of 4.2% from the $3.11 reported in fiscal 2024. However, the EPS is projected to see a slight increase to approximately $3 in fiscal 2026.

Stock Performance Analysis

PFE’s stock has not fared well recently, underperforming against the S&P 500’s ($SPX) 6.6% gain over the past year. During this period, shares have decreased by 13.4%. This underperformance is also evident in comparison to the Health Care Select Sector SPDR Fund’s (XLV) minor dip.

Challenges Ahead

The decline in performance can be attributed to decreasing demand for COVID-19 related products and looming patent expirations for key medications, including Eliquis. The anticipated introduction of generic versions of Eliquis in 2028 could notably impact Pfizer’s revenue. Additionally, the loss of exclusivity for other prominent products like Ibrance is expected to further detract from revenue and possibly contribute to a drop in share prices.

Recent Quarterly Results

On February 4, following the announcement of its Q4 results, PFE shares fell by more than 1%. The adjusted EPS of $0.63 surpassed Wall Street’s expectations of $0.48. Additionally, the company reported revenue of $17.8 billion, above the expected $17.5 billion. For the upcoming full year, Pfizer forecasts an adjusted EPS between $2.80 and $3, with revenue projected to fall between $61 billion and $64 billion.

Analysts’ Consensus on Pfizer Stock

The consensus opinion on PFE Stock leans toward a “Moderate Buy,” with 22 analysts covering the stock. Among them, eight recommend a “Strong Buy,” 13 suggest a “Hold,” while one advises a “Strong Sell.” The average price target for Pfizer is set at $29.80, pointing to a potential upside of 32.8% from the current trading levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information, please view the Barchart Disclosure Policy here.

More news from Barchart

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.